a) Antimicrobial Properties: The aqueous concentration of silver ions released from the nanocrystalline film is approximately 3% of that released from a 0.5% silver nitrate or a 1% silver sulfadiazine cream. However, the biological properties of the silver released from nanocrystals are much greater. Silver resistance has been reported in the literature and is mediated through one of two pathways. Either the silver is tied up in the cell wall and membranes, or it is actively transported out of the cell. Bacterial organisms that have either one of these resistance mechanisms, which are effective up to 1000 µg/mL Ag+, have been tested against the nanocrystalline silver coated dressing. These tests showed that these organisms were susceptible to the silver produced by the nanocrystals, but not to Ag+ from silver nitrate. These findings, as will be described, strongly suggest that other species of silver besides Ag+ are released from the nanocrystals.
Friday, February 27, 2009
Nanoparticles as Antimicrobial agents
a) Antimicrobial Properties: The aqueous concentration of silver ions released from the nanocrystalline film is approximately 3% of that released from a 0.5% silver nitrate or a 1% silver sulfadiazine cream. However, the biological properties of the silver released from nanocrystals are much greater. Silver resistance has been reported in the literature and is mediated through one of two pathways. Either the silver is tied up in the cell wall and membranes, or it is actively transported out of the cell. Bacterial organisms that have either one of these resistance mechanisms, which are effective up to 1000 µg/mL Ag+, have been tested against the nanocrystalline silver coated dressing. These tests showed that these organisms were susceptible to the silver produced by the nanocrystals, but not to Ag+ from silver nitrate. These findings, as will be described, strongly suggest that other species of silver besides Ag+ are released from the nanocrystals.
Nanotechnology in Medicine
The longer range future of nanotechnology in medicine is referred to as nanomedicine. This involves the use of manufactured nano-robots to make repairs at the cellular level.
Nanomedicine refers to future developments in medicine that will be based on the ability to build nanorobots. In the future these nanorobots could actually be programmed to repair specific diseased cells, functioning in a similiar way to antibodies in our natural healing processes.
Nanotechnology in Medicine: Current Applications
While most applications of nanotechnology in medicine are still under development nanocrystalline silver is already being used as a antimicrobial agent in the treatment of wounds.
Nanotechnology in Medicine: Applications under Development
Qdots that identify the location of cancer cells in the body.
Nanoparticles that deliver chemotherapy drugs directly to cancer cells to minimize damage to healthy cells.
Nanoshells that concentrate the heat from infrared light to destroy cancer cells with minimal damage to surrounding healthy cells.
Nanotubes used in broken bones to provide a structure for new bone material to grow.
Nanoparticles that can attach to cells infected with various diseases and allow a doctor to identify, in a blood sample, the particular disease.
Developing Nanorobots for Nanomedicine
Design analysis for a cell repair nanorobot: The Ideal Gene Delivery Vector: Chromallocytes, Cell Repair Nanorobots for Chromosome Repair TherapyDesign analysis for an antimicrobial nanorobot: Microbivores: Artifical Mechanical Phagocytes using Digest and Discharge ProtocolA Mechanical Artificial Red Cell: Exploratory Design in Medical Nanotechnology
New molecular entities approved by the US FDA's Center for Drug Evaluation and Research in 2008
FROM THE FOLLOWING ARTICLE:
Bethan Hughes
Nature Reviews Drug Discovery 8, 93-96 (February 2009)
doi:10.1038/nrd2813
Generic name (Trade name) Company* Indication(URL of label information if available) Properties Date Etravirine (Intelence) Tibotec HIV-1(http://www.fda.gov/cder/foi/label/2008/022187lbl.pdf) Non-nucleoside reverse transcriptase inhibitor 18 Jan (P) Desvenlafaxine (Pristiq) Wyeth Major depressive disorder(http://www.fda.gov/cder/foi/label/2008/021992lbl.pdf) Selective serotonin and noradrenaline reuptake inhibitor 29 Feb (S) Bendamustine hydrochloride (Treanda) Cephalon Chronic lymphocytic leukaemia(http://www.fda.gov/cder/foi/label/2008/022249lbl.pdf) Mechlorethamine derivative with DNA-alkylating activity 20 Mar (P, O) Regadenoson (Lexiscan) CV Therapeutics Pharmacological stress agent for radionuclide imaging (http://www.fda.gov/cder/foi/label/2008/022161lbl.pdf) A2A adenosine receptor agonist 10 Apr (S) Methylnaltrexone bromide (Relistor) Progenics Opioid-induced constipation Peripherally acting opioid receptor antagonist 24 Apr (S) Alvimopan (Entereg) Adolor To accelerate gastrointestinal recovery following bowel resection surgery(http://www.fda.gov/cder/foi/label/2008/021775lbl.pdf) Peripherally acting opioid receptor antagonist 20 May (S) Difluprednate (Durezol) Sirion Inflammation and pain associated with ocular surgery (http://www.fda.gov/cder/foi/label/2008/022212lbl.pdf) Ocular corticosteroid thought to act by the induction of phospholipase A2 inhibitory proteins 23 Jun (P) Gadoxetate disodium (Eovist) Bayer Gadolinium-based contrast agent(http://www.fda.gov/cder/foi/label/2008/022090lbl.pdf) Paramagnetic compound 3 Jul (S) Clevidipine butyrate (Cleviprex) The Medicines Company Peri-operative hypertension when oral therapy is not feasible or not desirable Short-acting dihydropyridine calcium channel antagonist 1 Aug (S) Tetrabenazine (Xenazine) Prestwick Chorea associated with Huntington's disease(http://www.fda.gov/cder/foi/label/2008/021894lbl.pdf) Monoamine-depleting agent 15 Aug (P, O) Iobenguane I-123 (AdreView) GE Healthcare Radiopharmaceutical agent for the detection of primary or metastatic phaeochromocytoma or neuroblastoma (http://www.fda.gov/cder/foi/label/2008/22290lbl.pdf) Taken up by the noradrenaline transporter in adrenergic nerve terminals 19 Sep (P, O) Silodosin (Rapaflo) Watson Benign prostatic hyperplasia(http://www.fda.gov/cder/foi/label/2008/022206lbl.pdf) 1 adrenoceptor antagonist 8 Oct (S) Lacosamide (Vimpat) Schwarz Partial-onset seizures in epilepsy (http://www.fda.gov/cder/foi/label/2008/022253lbl.pdf) Selectively enhances slow inactivation of voltage-gated sodium channels and binds to collapsin response mediator protein 2 28 Oct (S) Fesoterodine fumarate (Toviaz) Pfizer Overactive bladder disorder(http://www.fda.gov/cder/foi/label/2008/022030lbl.pdf) Competitive muscarinic receptor antagonist 31 Oct (S) Rufinamide (Banzel) Eisai Seizures associated with Lennox–Gastaut syndrome (http://www.fda.gov/cder/foi/label/2008/021911lbl.pdf) Sodium channel activity modulator 14 Nov (S) Eltrombopag (Promacta) GlaxoSmithKline Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (http://www.fda.gov/cder/foi/label/2008/022291lbl.pdf) Thrombopoietin receptor agonist 20 Nov (P, O) Tapentadol hydrochloride‡ Ortho–McNeil–Janssen Moderate to severe acute pain opioid receptor agonist and noradrenaline reuptake inhibitor 20 Nov (S) Fospropofol disodium (Lusedra) Eisai Monitored anaesthesia care sedation (http://www.fda.gov/cder/foi/label/2008/022244lbl.pdf) Prodrug of propofol 12 Dec (S) Plerixafor (Mozobil) Genzyme Autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma (http://www.fda.gov/cder/foi/label/2008/022311lbl.pdf) CXCR4 antagonist 15 Dec (P, O) Gadofosveset (Vasovist) Epix Gadolinium-based contrast agent Paramagnetic compound 22 Dec (S) Degarelix (Firmagon) Ferring Advanced prostate cancer (http://www.fda.gov/cder/foi/label/2008/022201lbl.pdf) Gonadotropin-releasing hormone receptor antagonist 24 Dec (S) *The company that submitted the original new drug application to the US FDA.‡Trade name not available at the time of going to press. O, FDA orphan designation; P, FDA priority review; S, FDA standard review.
Free Books, powerpoint presentations, teaching tools and resources and drug information
-
Microbiology Lecture Notes - SET 4 - Powerpoint links collected from the website of : Lauren Brandon, Ph.D , Associate Professor of Microbiology Introduction to Microbiology Microbial Cell...7 years ago
-
Is Vitapulse a Scam? - The heart is a vital organ of the body and it plays major roles in its general functioning. Proper healthcare should be taken to ensure the heart functio...8 years ago
-
Atypical Thyrotoxicosis Relapse after Carbimazole Discontinuation: A Case Report with Pharmacological View - authors: Sharique Ahmad, Saeeda Wasim, Mohammed Tariq Salman, Mohammed Aqwam Siddiqui, Nahid Shabnam, Pragya Khanna A 15-year-old girl who presented with p...9 years ago
-
Ranking of Indian Repositories - Ranking of Indian Repositories based on Ranking of Web of World Repositories, January 2009 Edition. World Ranking among all types of Repositories ...15 years ago
-
For Computer-lOvErS - *Antivirus SofTwArEs* Norton 360 (Up To 12 Years Key) Norton AntiVirus 2008 AVG Antivirus Panda.Antivirus NOD32 Antivirus Kingsoft Antivirus Kaspersky...16 years ago
-
Contemporary Targeted Therapies in Rheumatology - Publisher: Informa Healthcare Number Of Pages: 636 Publication Date: 2007-10-24 ISBN-10 / ASIN: 1841844845 ISBN-13 / EAN: 9781841844848 Binding: Hardcover ...16 years ago
-
-
-
-
-
-
-